Published • loading... • Updated
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines, Further Expanding Their Inflammation Pipeline
Summary by bionity.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Gilead Sciences, Inc. and Lakefront Biotherapeutics NV announced the successful completion of their previously announced acquisition of Ouro Medicines to advance T-cell engager therapies for autoimmune diseases. The acquisition expands Gilead's growing inflammatory disease portfolio with games...
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
